Company profile
Insmed Incorporated
Pipeline9 assets
- BrensocatibBRINSUPRI / DPP1 / Small Molecule / Respiratory / ImmunologyNon-Cystic Fibrosis Bronchiectasis (NCFB)MarketedActiveUSEUHidradenitis SuppurativaPhase 2ActiveGlobal
- Amikacin Liposome Inhalation SuspensionARIKAYCE / Bacterial 30S ribosomal subunit / Liposomal Inhalation Suspension / Respiratory / Infectious DiseaseRefractory Mycobacterium avium complex (MAC) Lung DiseaseMarketedActiveUSEUJPMAC Lung Disease (Label Expansion)Phase 3ActiveGlobal
- Treprostinil Palmitil Inhalation PowderTPIP / Prostacyclin receptor / Inhalation Powder / Respiratory / PulmonaryPulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)Phase 3ActiveGlobalPulmonary Arterial Hypertension (PAH)Phase 3ActiveGlobalProgressive Pulmonary Fibrosis (PPF)Phase 3 PlannedActiveGlobal
- INS1148INS1148 / Stem Cell Factor SCF248 / Monoclonal Antibody / Respiratory / ImmunologyInterstitial Lung Disease (ILD)Phase 2ActiveGlobalModerate-to-severe asthmaPhase 2ActiveGlobal
- INS1033INS1033 / Unknown / Unknown / Immunology & InflammationInflammatory diseasesPreclinicalActiveGlobal
- Intrathecal gene therapy for DMDDystrophin / Gene Therapy / Neurology / Rare DiseaseDuchenne Muscular Dystrophy (DMD)Phase 1ActiveGlobal
- INS1202INS1202 / Unknown / Unknown / Neurology / Rare DiseaseAmyotrophic Lateral Sclerosis (ALS)Phase 1ActiveGlobal
- Stargardt Disease Gene TherapyUnknown / Gene Therapy / Ophthalmology / Rare DiseaseStargardt DiseasePreclinicalActiveGlobal
- Next-Gen DPP1 InhibitorsDPP1 / Small Molecule / Immunology & InflammationUndisclosedPreclinicalActiveGlobal
Latest news18 items
All newsInsmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Presentation / Abstract • Phase 3ERS oral presentation Sun, Sep 6, 2026, 9:30 AM CEST
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
Results Call • Phase 2Results call Thu, Jul 16, 2026, 8:00 AM ET
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
Trial Results • Phase 3